28 June 2018 13:30 BST
Agreement with Luye Pharma Group for rights to Seroquel and Seroquel XR
in the UK, China and other international markets completed
AstraZeneca today completed an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa.
Under the terms of the agreement, AstraZeneca has received a payment of $260m from Luye Pharma as part of the total $538m consideration. Further payments of $240m and $38m are due in December 2019 and July 2020, respectively, and a milestone payment is also due on the successful transition of certain activities to Luye Pharma. The present value of the upfront and future payments will be reported as Other Operating Income in the Company's financial statements in the second quarter of 2018.
About Seroquel
Seroquel (quetiapine fumarate, immediate release, IR) and Seroquel XR (extended release formulation) are atypical, anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations |
|
|
Karen Birmingham |
UK/Global |
+44 203 749 5634 |
Rob Skelding |
UK/Global |
+44 203 749 5821 |
Matt Kent |
UK/Global |
+44 203 749 5906 |
Gonzalo Viña |
UK/Global |
+44 203 749 5916 |
Jacob Lund |
Sweden |
+46 8 553 260 20 |
Michele Meixell |
US |
+1 302 885 2677 |
|
|
|
Investor Relations |
|
|
Thomas Kudsk Larsen |
|
+44 203 749 5712 |
Josie Afolabi |
|
+44 203 749 5631 |
Craig Marks |
Finance; Fixed Income; M&A |
+44 7881 615 764 |
Henry Wheeler |
Oncology |
+44 203 749 5797 |
Mitchell Chan |
Oncology; Other |
+1 240 477 3771 |
Christer Gruvris |
Brilinta; Diabetes |
+44 203 749 5711 |
Nick Stone |
Respiratory; Renal |
+44 203 749 5716 |
Jennifer Kretzmann |
Retail Investors |
+44 203 749 5824 |
US toll-free |
|
+1 866 381 7277 |
|
|
|
Adrian Kemp
Company Secretary
AstraZeneca PLC